As of 14 Oct 2026, Verdiva Bio has raised $411M across 1 verified round on record; latest: $411 million Series A led by Forbion and General Atlantic, announced 9 Jan 2025.
Verdiva Bio develops next-generation medicines aimed at treating obesity and cardiometabolic diseases.
verdivabio.comLinkedInLondon and San FranciscoBiotech
1 source
The source page is dated 13 January 2025, but the release dateline fixes the announcement to 9 January 2025. London and San Francisco are dateline locations, not a headquarters statement.
Published by hand (bioindustry.org): "Verdiva launches with an oversubscribed Series A financing of $411 million.": biggest-rounds completeness (K): hand-checked, the cited page states $411 million
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $411M | 2025-01-09 | Forbion, General Atlantic | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source
The source page is dated 13 January 2025, but the release dateline fixes the announcement to 9 January 2025. London and San Francisco are dateline locations, not a headquarters statement. Published by hand (bioindustry.org): "Verdiva launches with an oversubscribed Series A financing of $411 million.": biggest-rounds completeness (K): hand-checked, the cited page states $411 million | ||||